FindTrial
Sign In

Comparing the Dosimetric Effects of Sequential and Simultaneously-Integrated Boost in Breast Cancer Patients After Breast-Conserving Surgery

Dosimetric Evaluation of Sequential Boost versus Simultaneously-Integrated Boost in Patients with Breast Cancer Post Breast-Conserving Surgery - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/12/077538
Enrollment
40
Registered
2024-12-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50-C50- Malignant neoplasms of breast

Interventions

Control Intervention1: NIL: NIL

Sponsors

Dr. Rahul Thakur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age more than 18 years Female patients Biopsy proven invasive breast cancer Post operative breast cancer patients having standard indication of radiation therapy

Exclusion criteria

Exclusion criteria: Prior radiotherapy to breast Recurrent disease Metastatic disease

Design outcomes

Primary

MeasureTime frame
To evaluate the dosimetric plans in patients treated with two distinct boost techniques i.e. SIB and SEQBsTimepoint: To evaluate the dosimetric plans in patients treated with two distinct boost techniques i.e. SIB and SEQBs—

Secondary

MeasureTime frame
To evaluate the dose received by Planning Target Volume (PTV) and Organs at Risk (OAR) during IMRT and HT techniques in breast cancer patients treated via: a. SIB plan and b. SEQBs plan Timepoint: To evaluate the dose received by Planning Target Volume (PTV) and Organs at Risk (OAR) during IMRT and HT techniques in breast cancer patients treated via: a. SIB plan and b. SEQBs plan—

Countries

India

Contacts

Public ContactDr Rashi Agrawal

Max Super Specialty Hospital

drrashi.ag@gmail.com09891483550

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026